Kiromic BioPharma, Inc. (KRBP)

Market Cap	399.93K
Revenue (ttm)	n/a
Net Income (ttm)	-35.41M
Shares Out	1.18M
EPS (ttm)	-55.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,722
Open	0.403
Previous Close	0.385
Day's Range	0.290 - 0.415
52-Week Range	0.290 - 15.300
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2023

About KRBP

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 31
• Stock Exchange: OTCMKTS
• Ticker Symbol: KRBP